Pregled bibliografske jedinice broj: 1134887
Safety of relaxing coagulation control by anti- tissue factor pathway inhibitor in hemophilia patients: Impact of tissue distribution of tissue factor
Safety of relaxing coagulation control by anti- tissue factor pathway inhibitor in hemophilia patients: Impact of tissue distribution of tissue factor // Journal of thrombosis and haemostasis, 18 (2020), 9; 2412-2414 doi:10.1111/jth.14955. (međunarodna recenzija, pismo, znanstveni)
CROSBI ID: 1134887 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Safety of relaxing coagulation control by anti-
tissue factor pathway inhibitor in hemophilia
patients: Impact of tissue distribution of tissue
factor
Autori
Boban, Ana ; Hermans, Cedric
Izvornik
Journal of thrombosis and haemostasis (1538-7933) 18
(2020), 9;
2412-2414
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, znanstveni
Ključne riječi
adverse effects, hemophilia, tissue factor, tissue factor pathway inhibitor, thrombosis,
Sažetak
In patients with hemophilia the beneficial pro- hemostatic effects of inhibiting tissue factor pathway inhibitor (TFPI) in tissues where tissue factor (TF) expression is low such as the joints could be compromised by the prothrombotic effects of TFPI inhibition in tissues where TF is higher constitutively or upon stimulation. The concomitant treatment with TFPI inhibitors and rFVIIa, aPCC or FVIII/FIX concentrates should be cautiously evaluated, due to their synergistic procoagulant effect.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Ana Boban
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
